Wednesday, February 17, 2016

News: BONESUPPORT™ Reports Expansion Of Company's CERAMENT™ Drug Eluting Procedure Registry

LUND, SwedenFeb. 2, 2016 /PRNewswire/ -- BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today provided an update on the Company's CERAMENT procedure registry, established by BONESUPPORT in February 2014 as part of the proactive post-market surveillance process for the Company's novel antibiotic eluting injectable bone substitutes.  The CERAMENT|G registry now includes 230 cases conducted in 18 hospitals across 9 countries.  In addition, the registry has recently been updated to include CERAMENT V procedures.
The CERAMENT|G registry includes a variety of complex procedures, including bone tumors, primary and revision hip and knee prostheses, osteomyelitis and infected diabetic foot.  Moreover, the registry participants include a number of world-renowned surgeons, including Professor Carlo Romanò, Istituto Ortopedico Galeazzi, Milan Italy, Mr. Martin McNally, Nuffield Orthopaedic Centre in Oxford, United Kingdom and Professor Guido Wanner, University Hospital of Zurich, Switzerland.  The CERAMENTregistry provides the ability to add more hospitals, more indications and more product line extensions and is one of the most robust registries in the industry.
"This important registry offers hospitals the opportunity to share CERAMENT data with a view to analyzing inter-country or cross-country trends," said Professor McNally.  "I am pleased to be participating in, and contributing to this registry.  We have shown that CERAMENT|G is a safe and effective addition to the management of many complex indications, including chronic osteomyelitis, and look forward to generating further data to confirm this."
 "We are excited about the diverse set of procedures and compelling data being generated in our CERAMENT registry," saidRichard Davies, CEO of BONESUPPORT.  "This registry both ensures vigilance in the post-marketing surveillance for our products, and allows the data generated from these complex procedures to be collected and stored in a central location.  We intend to work with our surgeon participants to ensure publication of this data in the future."
BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT|G and CERAMENT V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT|G and CERAMENT V are not available in the United States.
CERAMENT is a fully developed product platform that is commercially available in the U.S., EuropeSE Asia and the Middle East. CERAMENT is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over fifty pre-clinical, and clinical studies have been conducted and more than 20,000 patients have been treated with CERAMENT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit
Investor and Press Inquiries:
Offer Nonhoff
Chief Financial Officer
Phone +46 46 286 53 60

Published at PRNewsWire

No comments:

Post a Comment